Media headlines about DexCom (NASDAQ:DXCM) have been trending positive this week, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.26 on AlphaOne’s scale. AlphaOne also gave media stories about the medical device company an impact score of 87 out of 100, meaning that recent news coverage is very likely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted AlphaOne Sentiment’s rankings:
- Kevin R. Sayer Sells 8,649 Shares of DexCom, Inc. (DXCM) Stock (americanbankingnews.com)
- ETFs with exposure to DexCom, Inc. : May 18, 2017 (finance.yahoo.com)
- The Wedbush Securities Inc. Purchases New Stake in DexCom, Inc. (DXCM) – BangaloreWeekly (bangaloreweekly.com)
- What's Alphabet Got to Do With Healthcare? (finance.yahoo.com)
- DexCom : Announces Upcoming Conference Presentation (4-traders.com)
DexCom (NASDAQ:DXCM) opened at 67.66 on Friday. The firm has a 50-day moving average of $75.47 and a 200-day moving average of $73.57. The stock’s market cap is $5.84 billion. DexCom has a 1-year low of $57.68 and a 1-year high of $96.38.
DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.06. DexCom had a negative return on equity of 23.61% and a negative net margin of 10.64%. The business had revenue of $142.30 million during the quarter, compared to the consensus estimate of $143.94 million. Analysts expect that DexCom will post ($0.68) EPS for the current fiscal year.
Several analysts have commented on DXCM shares. B. Riley reaffirmed a “buy” rating and issued a $94.00 price objective on shares of DexCom in a research report on Monday, February 13th. Canaccord Genuity reissued a “buy” rating and issued a $95.00 price target on shares of DexCom in a research report on Friday, February 10th. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of DexCom in a research report on Thursday, April 13th. Northcoast Research reissued a “buy” rating on shares of DexCom in a research report on Wednesday, March 1st. Finally, Jefferies Group LLC boosted their price target on shares of DexCom from $80.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, March 1st. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and an average target price of $91.81.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/05/20/dexcom-dxcm-earns-media-impact-score-of-0-26-updated-updated-updated.html.
In other news, insider Terrance H. Gregg sold 15,000 shares of the stock in a transaction on Thursday, April 20th. The stock was sold at an average price of $74.10, for a total transaction of $1,111,500.00. Following the completion of the transaction, the insider now directly owns 454,559 shares in the company, valued at approximately $33,682,821.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Richard Doubleday sold 3,182 shares of the stock in a transaction on Thursday, February 23rd. The stock was sold at an average price of $78.42, for a total value of $249,532.44. Following the transaction, the executive vice president now owns 83,582 shares of the company’s stock, valued at $6,554,500.44. The disclosure for this sale can be found here. Insiders sold a total of 132,202 shares of company stock valued at $10,102,405 over the last ninety days. Corporate insiders own 2.80% of the company’s stock.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.